Provided by Tiger Fintech (Singapore) Pte. Ltd.

Aprea Therapeutics, Inc.

1.75
-0.0600-3.31%
Post-market: 1.830.0800+4.57%17:23 EDT
Volume:24.17K
Turnover:43.88K
Market Cap:9.68M
PE:-0.74
High:1.87
Open:1.80
Low:1.75
Close:1.81
Loading ...

Aprea Therapeutics Reports First Quarter 2025 Financial Results and Provides a Clinical Update

THOMSON REUTERS
·
14 May

Aprea Therapeutics Q1 EPS USD -0.66

THOMSON REUTERS
·
14 May

Aprea Therapeutics Inc expected to post a loss of 86 cents a share - Earnings Preview

Reuters
·
10 May

Aprea Therapeutics Inc -Open Label Data From Study Are Expected in Second Half of 2025

THOMSON REUTERS
·
31 Mar

Aprea Therapeutics Inc -Dosing of Patient With Hpv+ Head and Neck Squamous Cell Carcinoma (Hnscc) in Ongoing Acesot-1051 Trial

THOMSON REUTERS
·
31 Mar

Aprea Therapeutics Full Year 2024 Earnings: Beats Expectations

Simply Wall St.
·
26 Mar

Aprea Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
25 Mar

Aprea Therapeutics Q4 EPS ($0.49) Up From ($0.92) YoY.

Benzinga
·
25 Mar

Aprea Therapeutics Inc expected to post a loss of 69 cents a share - Earnings Preview

Reuters
·
21 Mar

BRIEF-Aprea Therapeutics Announces Agreement With MD Anderson Cancer Center To Explore Apr-1051 As A Potential Treatment For Head And Neck Squamous Cell Carcinoma (Hnscc)

Reuters
·
11 Mar

Aprea Therapeutics provides update on existing patent portfolio

TipRanks
·
06 Feb

Aprea Therapeutics Announces Strategic Ip Portfolio Evolution in DNA Damage Response (Ddr) Cancer Therapeutics

THOMSON REUTERS
·
05 Feb

BRIEF-Aprea Therapeutics Announces Twice Daily (Bid) Dosing Of Patients In ABOYA-119 Clinical Trial Of ATRN-119 To Potentially Optimize Clinical Outcomes

Reuters
·
11 Dec 2024

Aprea Therapeutics announces first patient dosed in ABOYA-119 Phase 1/2a trial

TIPRANKS
·
11 Dec 2024

Aprea Therapeutics- Dose Escalation in Aboya-119 Trial Expected to Continue With Both Once-Daily & Twice-Daily Dosing Schedules

THOMSON REUTERS
·
11 Dec 2024

Aprea Therapeutics Announces Twice Daily (Bid) Dosing of Patients in Aboya-119 Clinical Trial of Atrn-119 to Potentially Optimize Clinical Outcomes and Strengthen Clinical Path Forward

THOMSON REUTERS
·
11 Dec 2024

Aprea Therapeutics Inc -Anticipates Phase 1 Readout in Second Half of 2025

THOMSON REUTERS
·
11 Dec 2024